Defence contracts
Regeneron Pharmaceuticals Awarded $2.625 Billion Contract for COVID-19 Therapeutic
Regeneron Pharmaceuticals Inc. has been awarded a significant contract by the US Department of Defense to provide 1.25 million courses of a monoclonal antibody therapeutic for COVID-19. This treatment, a combination of casirivimab and imdevimab, has shown promise in combating the virus. The contract, valued at $2.625 billion,